Search

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.

Targeting HER2 in cancer

Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Exploring beyond boundaries for innovation in animal health

Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.

Patient Centricity

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.

Horses

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

PDF Download: Heartworm Disease in Dogs | Boehringer Ingelheim US

View our PDF download options on information on heartworm disease in dogs. Find out everything you need to know on prevention, symptoms and treatment.

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Poultry

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

FDA accepts Jardiance sNDA for T2D in children 10 and older

The US FDA has accepted a supplemental New Drug Application for Jardiance® (empagliflozin) tablets as a potential treatment for children 10 years and older with type 2 diabetes

History

Partnering Interests

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

BI & Eli Lilly & Co. Update for TRADJENTA® & JENTADUETO® | Boehringer Ingelheim US

Read about the approved updates to the PI for Tradjenta® (linagliptin) tablets and Jentadueto® (linagliptin & metformin HCI). View ISI, PI and Med Guide.

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

New GPP Consensus Statement Released

National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)

More Health Overview

Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.

FDA Grants Priority Review for Spesolimab | BI US

Read more about Spesolimab, which has been approved by the FDA as a treatment option for generalized pustular psoriasis (GPP) flares in adults.

African Swine Fever: Important Facts | Boehringer Ingelheim US

Click here to read more on the Boehringer Ingelheim efforts to understand and create a vaccine to prevent African Swine Fever in livestock across the globe.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage

Yew Looi Liew Named President of U.S. Human Pharma for Boehringer Ingelheim Pharmaceuticals, Inc.

Targeting HER2 in cancer

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

Exploring beyond boundaries for innovation in animal health

Patient Centricity

First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US

Horses

FDA Provides Full Approval to Praxbind, Specific Reversal Agent for Pradaxa

FDA Approves Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate)

PDF Download: Heartworm Disease in Dogs | Boehringer Ingelheim US

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

Poultry

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

FDA accepts Jardiance sNDA for T2D in children 10 and older

History

Partnering Interests

U.S. FDA approves supplemental New Drug Applications to include landmark data in product labels for Synjardy® (empagliflozin/metformin hydrochloride), Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) and Glyxambi® (empagliflozin/linag

BI & Eli Lilly & Co. Update for TRADJENTA® & JENTADUETO® | Boehringer Ingelheim US

U.S. FDA approves Synjardy® XR (empagliflozin/metformin hydrochloride extended-release) tablets for adults with type 2 diabetes

New GPP Consensus Statement Released

More Health Overview

FDA Grants Priority Review for Spesolimab | BI US

African Swine Fever: Important Facts | Boehringer Ingelheim US